



## Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

DUBLIN--(BUSINESS WIRE)--Jun. 3, 2026-- [Alkermes plc](#) (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47<sup>th</sup> Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on [www.alkermes.com](http://www.alkermes.com) and will be archived for 14 days.

### **About Alkermes plc**

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson's disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260603267022/en/>

Alkermes Contact:  
Sandy Coombs  
Investor Relations  
+1 781 609 6377

Source: Alkermes plc